VivoSeq
Oncology

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

4

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome is an early-stage landscape with 4 programs across 4 companies. The most active players are Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Incyte, AbbVie. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 1Incyte logo

Incyte

1 program

Phase 1AbbVie logo

AbbVie

1 program

Phase 1K

Kura Oncology, Inc.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Completed1 · 50%

Clinical Trials

Trial Activity

Phase I Study to Evaluate Safety of Ruxolitinib in Combination With Azacitidine + Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Recruiting·—·Phase 1·NCT03874052·51 enrolled
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Completed·National Cancer Institute (NCI)·Phase 3·NCT00093470·144 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)